艾拉莫德治疗强直性脊柱炎的疗效和安全性研究  

Clinical efficacy and safety of iguratimod in treatment of ankylosing spondylitis

作　　者：许百洁[1] 莫守崎 薛晓倩[1] 吴悦 Xu Baijie;Mo Shouqi;Xue Xiaoqian;Wu Yue(Department of Rheumatology and Immunology,Jieyang People’s Hospital,Jieyang 522000,China)

机构地区：[1]揭阳市人民医院风湿免疫科

出　　处：《新医学》2019年第12期915-918,共4页Journal of New Medicine

摘　　要：目的评估艾拉莫德在治疗强直性脊柱炎(AS)中的疗效与安全性。方法收集42例AS患者,随机分为观察组和对照组,每组各21例。观察组患者予艾拉莫德联合塞来昔布治疗,对照组使用柳氮磺胺吡啶片联合塞来昔布治疗,2组疗程均为24周。在治疗4、12、24周末评价疗效及安全性。结果治疗12周末及24周末,观察组达AS国际评估工作组反应指标(ASAS)20患者比例均高于对照组(P均<0.05),且观察组患者的背痛视觉模拟评分、Bath AS疾病活动性指数、Bath AS功能指数评分及ESR、CRP均低于对照组(P均<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论艾拉莫德能有效缓解AS患者病情,且安全性良好。Objective To evaluate the clinical efficacy and safety of iguratimod in the treatment of ankylosing spondylitis(AS).Methods A total of 42 AS patients were recruited and randomly assigned into the observation(n=21)and control groups(n=21).In the observation group,patients were treated with iguratimod combined with celecoxib,and those in the control group were treated with sulfasalazine in combination with celecoxib for 24 weeks.Clinical efficacy and safety were evaluated at 4,12 and 24 weeks after corresponding treatment.Results At 12 and 24 weeks,the proportion of patients reaching Achieving Assessment in Ankylosing Spondylitis 20(ASAS 20)in the observation group was significantly higher compared with that in the control group(both P<0.05).In addition,the Visual Analog Scale for spinal pain,Bath Ankylosing Spondylitis Disease Activity Index,Bath AS functional index,erythrocyte sedimentation rate(ESR)and C-reactive protein(CRP)in the observation group were remarkably lower than those in the control group(all P<0.05).The incidence of adverse events did not significantly differ between two groups(P>0.05).Conclusion Iguratimod can effectively alleviate AS with high safety.

关 键 词：艾拉莫德 强直性脊柱炎 风湿性疾病 疗效 安全性 

分 类 号：R59[医药卫生—内科学]